VDPV and VAPP

Vaccine-Associated Paralytic Poliomyelitis

Vaccine-associated paralytic poliomyelitis represents paralytic polio occurring in vaccine recipients or close contacts.
Causative agent involves poliovirus strain genetically altered in host intestine from original attenuated vaccine strain.
Diagnosis requires acute flaccid paralysis demonstrating residual paralysis lasting minimum 60 days.
Paralysis manifests in oral poliovirus vaccine recipients between 4 and 40 days following administration.
Paralysis manifests in known vaccine contacts between 7 and 60 to 75 days following administration.
Laboratory confirmation requires isolation of vaccine-related poliovirus from stool samples without wild poliovirus isolation.

Clinical presentation remains indistinguishable from paralytic poliomyelitis caused by wild virus.
Global incidence ranges from 2 to 4 cases per million births annually.
Highest risk follows initial oral vaccine dose, occurring in 1 per 2.9 million administered doses.
Initial dose recipients and contacts carry 6.6-fold higher risk compared to subsequent dose recipients.
Industrialized nations report cases primarily in early infancy during initial dosing.
Developing nations report gradual decline across subsequent doses, concentrating cases among children aged 1 to 4 years.
Type 3 poliovirus causes 42 percent of cases, followed by type 2 causing 26 percent, type 1 causing 20 percent, and mixed strains causing 15 percent.
Indian burden remains obscure due to classification under non-polio acute flaccid paralysis.
Indian risk remains comparatively lower due to maternal antibodies, birth dose administration, and lower vaccine uptake rates.

Sabin vaccine strains demonstrate genetic instability during replication in human gut.
Attenuated virus regains virulence through reversion of key attenuating mutations.
Lower immune responsiveness to oral vaccine and high prevalence of maternal antibodies facilitate prolonged replication.
Simultaneous administration of multiple serotypes causes interference, allowing dominant serotypes prolonged replication time.

Attenuated viruses in live oral vaccine reacquire neurovirulence and transmission capacity through extended replication and genetic divergence.
Genetic divergence exceeds 1 percent (or greater than 10 nucleotide changes) for poliovirus types 1 and 3.
Genetic divergence exceeds 0.6 percent (or greater than 6 nucleotide changes) for poliovirus type 2.
Mutated viruses circulate in communities for extended periods causing paralytic disease outbreaks.
Type 2 poliovirus accounts for approximately 90 percent of all vaccine-derived outbreaks globally.

Demonstrates active person-to-person transmission within community settings.
Requires isolation of genetically linked viruses from at least two individuals who are not household contacts.
Alternatively diagnosed via one human isolate combined with environmental surveillance samples, or multiple distinct environmental samples.
Capable of replicating efficiently at normal body temperature.

Isolated exclusively from individuals possessing primary B-cell or combined immunodeficiency disorders.
Immunocompromised state permits persistent chronic viral shedding.
Shed viruses demonstrate regained neurovirulence over extended carriage periods.

Low routine immunization coverage creates significant population immunity gaps.
Prior successful elimination of corresponding wild poliovirus serotype removes natural immunity.
Extensive historical reliance on monovalent and bivalent oral vaccines increases population susceptibility to type 2 strains.
Poor sanitation infrastructure facilitates unchecked fecal-oral viral transmission.
Insensitive acute flaccid paralysis surveillance delays outbreak detection and containment.

Feature	Vaccine-Associated Paralytic Poliomyelitis	Circulating Vaccine-Derived Poliovirus	Immunodeficiency-Associated Vaccine-Derived Poliovirus
Origin	Spontaneous mutation in single vaccinee or close contact.	Extended circulation and mutation in under-immunized community.	Chronic unchecked replication in immunodeficient host.
Transmission	Limited to immediate close contacts.	Active person-to-person community transmission.	Limited transmission, chronic individual shedding.
Genetic Drift	Minimal nucleotide changes.	>1% divergence (Types 1, 3) or >0.6% (Type 2).	Progressive divergence during chronic carriage.
Primary Serotype	Type 3 predominantly.	Type 2 predominantly (>90%).	Varies based on exposure.
Risk Factors	First vaccine dose, lack of maternal antibodies.	Low herd immunity, poor sanitation.	Primary B-cell or combined immunodeficiency.

Sequential administration utilizing inactivated polio vaccine followed by oral polio vaccine reduces or eliminates paralytic complication risks.
Inactivated vaccine bypasses intestinal interference, providing systemic immunity without risk of reversion.
World Health Organization mandates inclusion of at least one inactivated vaccine dose in all national schedules to induce baseline immunity.
Inactivated vaccine administration prior to oral vaccine minimizes complication risks while ensuring adequate mucosal immunity to interrupt wild virus circulation.
Intradermal fractional doses of inactivated vaccine provide dose-sparing, cost-effective alternatives yielding comparable seroconversion following two doses.

Global coordinated withdrawal of trivalent oral vaccine and cessation of type 2 oral vaccine occurred in 2016.
Implementation of bivalent oral vaccine (types 1 and 3) targets remaining wild virus strains.
Development and emergency deployment of novel oral poliovirus vaccine type 2 directly addresses circulating vaccine-derived outbreaks.
Novel type 2 vaccine features genetic stabilization, significantly reducing likelihood of reversion to neurovirulent forms in low immunity settings.
Sabin-inactivated poliovirus utilizes attenuated strains for manufacture, reducing biosafety risks and enabling affordable mass production in developing nations.
Enhanced environmental surveillance and reverse cold chain transport of stool samples ensure rapid detection and genomic sequencing of divergent strains.